Pseudotyped retrovirus with modified ebola glycoprotein
AssigneesPurdue Research Foundation, Centers for Disease Control and Prevention
InventorsDavid A. Sanders, Scott A. Jeffers, Anthony Sanchez
Life of this patent
Estimating the term…
Abstract
Pseudotyped retroviruses having viral glycoproteins with modified O glycosylation regions are provided. Also provided are methods for making the pseudotyped retroviruses of the present invention and for using the pseudotyped retroviruses for transduction of target cells. Cells for stably producing the pseudotyped retroviruses or the present invention are also provided.
Claims7
A pseudotyped retrovirus comprising a recombinant RNA associated with a retroviral core surrounded by a lipid bilayer having disposed therein modified Ebola glycoprotein, wherein the modified glycoprotein contains a deletion of amino acids 309-489 in the O-glycosylation region of a wild-type Ebola glycoprotein encoded by SEQ ID NO:1, wherein the recombinant RNA comprises (i) a nucleotide sequence defining a selected biomolecule intended for delivery to a target cell, and (ii) retroviral control elements for packaging, reverse transcription and integration of the retrovirus into a target cell, and wherein the pseudotyped retrovirus has a transduction efficiency into a target cell of at least 2-fold higher than a retrovirus pseudotyped with the wild-type Ebola glycoprotein.
A recombinant retrovirus pseudotyped with a modified Ebola glycoprotein lacking amino acids 309-489 in the O-glycosylation region of a wild-type Ebola glycoprotein encoded by SEQ ID NO:1, wherein said recombinant retrovirus has a transduction efficiency into a target cell of at least 2-fold higher than a retrovirus pseudotyped with the wild-type glycoprotein.
Dependencies are inferred from the claim text.